169 related articles for article (PubMed ID: 29807073)
1. Catalytic domain mutation in CYLD inactivates its enzyme function by structural perturbation and induces cell migration and proliferation.
Johari T; Maiti TK
Biochim Biophys Acta Gen Subj; 2018 Sep; 1862(9):2081-2089. PubMed ID: 29807073
[TBL] [Abstract][Full Text] [Related]
2. [Research progress of deubiquitinating enzyme CYLD to regulate liver-related diseases].
Yang X; An DJ; Gao CC; Qin HY
Zhonghua Gan Zang Bing Za Zhi; 2019 Jun; 27(6):477-480. PubMed ID: 31357769
[TBL] [Abstract][Full Text] [Related]
3. CYLD: a tumor suppressor deubiquitinase regulating NF-kappaB activation and diverse biological processes.
Sun SC
Cell Death Differ; 2010 Jan; 17(1):25-34. PubMed ID: 19373246
[TBL] [Abstract][Full Text] [Related]
4. CYLD Inhibits the Development of Skin Squamous Cell Tumors in Immunocompetent Mice.
Alameda JP; García-García VA; López S; Hernando A; Page A; Navarro M; Moreno-Maldonado R; Paramio JM; Ramírez Á; García-Fernández RA; Casanova ML
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201751
[TBL] [Abstract][Full Text] [Related]
5. miR-182 controls cell growth in gastrointestinal stromal tumors by negatively regulating CYLD expression.
Ling T; Yu F; Cao H
Oncol Rep; 2018 Dec; 40(6):3705-3713. PubMed ID: 30542706
[TBL] [Abstract][Full Text] [Related]
6. CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members.
Trompouki E; Hatzivassiliou E; Tsichritzis T; Farmer H; Ashworth A; Mosialos G
Nature; 2003 Aug; 424(6950):793-6. PubMed ID: 12917689
[TBL] [Abstract][Full Text] [Related]
7. The structure of the CYLD USP domain explains its specificity for Lys63-linked polyubiquitin and reveals a B box module.
Komander D; Lord CJ; Scheel H; Swift S; Hofmann K; Ashworth A; Barford D
Mol Cell; 2008 Feb; 29(4):451-64. PubMed ID: 18313383
[TBL] [Abstract][Full Text] [Related]
8. Update of cylindromatosis gene (CYLD) mutations in Brooke-Spiegler syndrome: novel insights into the role of deubiquitination in cell signaling.
Blake PW; Toro JR
Hum Mutat; 2009 Jul; 30(7):1025-36. PubMed ID: 19462465
[TBL] [Abstract][Full Text] [Related]
9. Cylindromatosis Is Required for Survival of a Subset of Melanoma Cells.
La T; Jin L; Liu XY; Song ZH; Farrelly M; Feng YC; Yan XG; Zhang YY; Thorne RF; Zhang XD; Teng L
Oncol Res; 2020 Sep; 28(4):385-398. PubMed ID: 32252875
[TBL] [Abstract][Full Text] [Related]
10. CYLD: a multifunctional deubiquitinase.
Glittenberg M; Ligoxygakis P
Fly (Austin); 2007; 1(6):330-2. PubMed ID: 18820455
[TBL] [Abstract][Full Text] [Related]
11. Five new CYLD mutations in skin appendage tumors and evidence that aspartic acid 681 in CYLD is essential for deubiquitinase activity.
Almeida S; Maillard C; Itin P; Hohl D; Huber M
J Invest Dermatol; 2008 Mar; 128(3):587-93. PubMed ID: 17851586
[TBL] [Abstract][Full Text] [Related]
12. Subquinocin, a small molecule inhibitor of CYLD and USP-family deubiquitinating enzymes, promotes NF-κB signaling.
Yamanaka S; Sato Y; Oikawa D; Goto E; Fukai S; Tokunaga F; Takahashi H; Sawasaki T
Biochem Biophys Res Commun; 2020 Mar; 524(1):1-7. PubMed ID: 31898971
[TBL] [Abstract][Full Text] [Related]
13. Premature aging and cancer development in transgenic mice lacking functional CYLD.
Alameda JP; Ramírez Á; García-Fernández RA; Navarro M; Page A; Segovia JC; Sanchez R; Suárez-Cabrera C; Paramio JM; Bravo A; Fernández-Aceñero MJ; Casanova ML
Aging (Albany NY); 2019 Jan; 11(1):127-159. PubMed ID: 30631004
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of LEF1 Impairs Myeloma Cell Growth Through Modulating CYLD/NF-κB Signaling.
Zhang G; Miao F; Liu K; Wu J; Xu J
Technol Cancer Res Treat; 2021; 20():15330338211034270. PubMed ID: 34269120
[TBL] [Abstract][Full Text] [Related]
15. Inactivation of deubiquitinase CYLD enhances therapeutic antibody production in Chinese hamster ovary cells.
Lu Y; Zhou Q; Han Q; Wu P; Zhang L; Zhu L; Weaver DT; Xu C; Zhang B
Appl Microbiol Biotechnol; 2018 Jul; 102(14):6081-6093. PubMed ID: 29766242
[TBL] [Abstract][Full Text] [Related]
16. miR-501 is upregulated in cervical cancer and promotes cell proliferation, migration and invasion by targeting CYLD.
Sanches JGP; Xu Y; Yabasin IB; Li M; Lu Y; Xiu X; Wang L; Mao L; Shen J; Wang B; Hou L; Ju J; Zhao J; Song B
Chem Biol Interact; 2018 Apr; 285():85-95. PubMed ID: 29477382
[TBL] [Abstract][Full Text] [Related]
17. Regulation of CYLD activity and specificity by phosphorylation and ubiquitin-binding CAP-Gly domains.
Elliott PR; Leske D; Wagstaff J; Schlicher L; Berridge G; Maslen S; Timmermann F; Ma B; Fischer R; Freund SMV; Komander D; Gyrd-Hansen M
Cell Rep; 2021 Oct; 37(1):109777. PubMed ID: 34610306
[TBL] [Abstract][Full Text] [Related]
18. miR-130b regulates the proliferation, invasion and apoptosis of glioma cells via targeting of CYLD.
Xiao ZQ; Yin TK; Li YX; Zhang JH; Gu JJ
Oncol Rep; 2017 Jul; 38(1):167-174. PubMed ID: 28534976
[TBL] [Abstract][Full Text] [Related]
19. The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination.
Kovalenko A; Chable-Bessia C; Cantarella G; Israël A; Wallach D; Courtois G
Nature; 2003 Aug; 424(6950):801-5. PubMed ID: 12917691
[TBL] [Abstract][Full Text] [Related]
20. Potential role of CYLD (Cylindromatosis) as a deubiquitinating enzyme in vascular cells.
Takami Y; Nakagami H; Morishita R; Katsuya T; Hayashi H; Mori M; Koriyama H; Baba Y; Yasuda O; Rakugi H; Ogihara T; Kaneda Y
Am J Pathol; 2008 Mar; 172(3):818-29. PubMed ID: 18245814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
